1. Clinical Overview
Olopatadine is a selective, potent, and long-acting histamine H1-receptor antagonist and mast cell stabilizer, primarily used for the symptomatic treatment of allergic conjunctivitis. The 5mg tablet formulation is indicated for systemic relief of allergic conditions such as allergic rhinitis and chronic urticaria. It exhibits a dual mechanism of action, providing rapid and sustained relief from allergic symptoms with a low incidence of sedation.
| Onset | Duration | Bioavailability |
|---|---|---|
| Oral: Within 1-2 hours. Ophthalmic: Within 3-5 minutes. | Approximately 24 hours for oral administration. | Approximately 72% following oral administration. |
2. Mechanism of Action
Olopatadine exerts its anti-allergic effects through a dual mechanism. It is a potent, selective antagonist of the histamine H1 receptor, competitively inhibiting the binding of histamine to its receptor on target cells (e.g., vascular endothelium, sensory nerves). Concurrently, it inhibits the antigen-induced release of inflammatory mediators (like histamine, tryptase, prostaglandin D2, and leukotrienes) from mast cells by stabilizing the mast cell membrane, preventing degranulation.
3. Indications & Uses
- Allergic Rhinitis (Seasonal and Perennial)
- Chronic Idiopathic Urticaria
4. Dosage & Administration
Adult Dosage: 5 mg orally, twice daily. May be taken with or without food.
Administration: Tablet should be swallowed whole with a glass of water. Can be taken without regard to meals. For allergic rhinitis, consistent daily use is more effective than as-needed use during the allergy season.
5. Side Effects
Common side effects may include:
- Headache
- Somnolence (drowsiness) - less than 5%
- Fatigue
- Dry mouth
- Pharyngitis
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Additive sedative effects; increased risk of drowsiness and impaired coordination. | Moderate |
| Ketoconazole, Erythromycin | No clinically significant pharmacokinetic interaction expected as Olopatadine is not metabolized by CYP450. No dosage adjustment needed. | Minor |
| Anticholinergic drugs (e.g., Atropine, TCAs) | Potential additive anticholinergic effects (dry mouth, blurred vision, urinary retention), though Olopatadine has low anticholinergic potency. | Low |
7. Patient Counselling
- DO take the medication as prescribed, usually twice daily.
- DO inform your doctor about all other medications you are taking.
- DO discontinue the drug and seek immediate medical attention if you experience swelling of face/lips, difficulty breathing, or severe rash.
- DONT drive or operate heavy machinery if you feel drowsy.
- DONT consume alcohol while on this medication.
- DONT stop taking the medication abruptly unless advised by your doctor.
8. Toxicology & Storage
Overdose: Symptoms may include severe drowsiness, dizziness, dry mouth, nausea, and headache. In massive overdose, CNS depression or paradoxical stimulation, and tachycardia may occur.
Storage: Store at room temperature (15-30°C), protected from light and moisture. Keep out of reach of children. Do not use after the expiry date printed on the pack.